{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:05Z","timestamp":1790957525882,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.aace.2020.11.009","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:00:17Z","timestamp":1609423217000},"page":"17-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature"],"prefix":"10.1016","volume":"7","author":[{"given":"Serena","family":"Mistry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre Cocks","family":"Eschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.aace.2020.11.009_bib1","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 Inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.aace.2020.11.009_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.aace.2020.11.009_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/nu11010169","article-title":"Role of ketogenic diets in neurodegenerative diseases (Alzheimer's disease and Parkinson's disease)","volume":"11","author":"Wlodarek","year":"2019","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.aace.2020.11.009_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dom.13012","article-title":"Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature","volume":"20","author":"Bonora","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.aace.2020.11.009_bib8","article-title":"Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis","volume":"2019","author":"Rafey","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"10166","key":"10.1016\/j.aace.2020.11.009_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.aace.2020.11.009_bib10","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.clinthera.2015.02.016","article-title":"Cardiometabolic effects of a new class of antidiabetic agents","volume":"37","author":"Desouza","year":"2015","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.aace.2020.11.009_bib11","first-page":"S49","article-title":"Safety of sodium-glucose co-transporter 2 inhibitors","volume":"132","author":"McGill","year":"2019","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.aace.2020.11.009_bib12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1464-5491.2008.02461.x","article-title":"Ketoacidosis occurs in both type 1 and type 2 diabetes--a population-based study from northern Sweden","volume":"25","author":"Wang","year":"2008","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/j.aace.2020.11.009_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.aace.2020.11.009_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.aace.2020.11.009_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcn\/nqy096","article-title":"Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments","volume":"108","author":"van Zuuren","year":"2018","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.aace.2020.11.009_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/bmjdrc-2016-000354","article-title":"Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes","volume":"5","author":"Snorgaard","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"10.1016\/j.aace.2020.11.009_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/jdi.12330","article-title":"Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet","volume":"6","author":"Hayami","year":"2015","journal-title":"J\u00a0Diabetes Investig"},{"issue":"2","key":"10.1016\/j.aace.2020.11.009_bib18","first-page":"e104","article-title":"Euglycemic diabetic ketoacidosis with SGLT2 inhibitor use in a patient on the atkins diet: a unique presentation of a known side effect","volume":"4","author":"Sood","year":"2018","journal-title":"AACE Clin Case Rep"},{"issue":"1","key":"10.1016\/j.aace.2020.11.009_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5694\/mja2.50434","article-title":"Euglycaemic ketoacidosis from an SGLT2 inhibitor exacerbated by a ketogenic diet","volume":"212","author":"Sinha","year":"2020","journal-title":"Med J Aust"},{"key":"10.1016\/j.aace.2020.11.009_bib20","first-page":"324","article-title":"Dapagliflozin and atkins diet in a patient with type 2 diabetes mellitus: a combination that should be avoided","volume":"56","author":"Grammatiki","year":"2018","journal-title":"Endocrine Abstracts"},{"issue":"2","key":"10.1016\/j.aace.2020.11.009_bib21","first-page":"185","article-title":"Euglycemic diabetic ketoacidosis in concurrent very low-carbohydrate diet and sodium-glucose transporter-2 inhibitor use: a case report","volume":"4","author":"Earle","year":"2020","journal-title":"Clin Pract Cases Emerg Med"},{"issue":"8","key":"10.1016\/j.aace.2020.11.009_bib22","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jc.2019-00139","article-title":"SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission","volume":"104","author":"Hamblin","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060520310105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060520310105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:31:58Z","timestamp":1762497118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376060520310105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2376060520310105"],"URL":"https:\/\/doi.org\/10.1016\/j.aace.2020.11.009","relation":{},"ISSN":["2376-0605"],"issn-type":[{"value":"2376-0605","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aace.2020.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}